A new trading day began on Monday, with Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock price up 3.40% from the previous day of trading, before settling in for the closing price of $7.35. RXRX’s price has ranged from $4.54 to $16.75 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 132.77% over the past five years. Meanwhile, its annual earnings per share averaged -9.14%. With a float of $146.66 million, this company’s outstanding shares have now reached $226.26 million.
Recursion Pharmaceuticals Inc (RXRX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 32.05%, while institutional ownership is 82.87%. The most recent insider transaction that took place on Apr 17 ’24, was worth 175,349. In this transaction Chief Financial Officer of this company sold 23,124 shares at a rate of $7.58, taking the stock ownership to the 1,231,055 shares. Before that another transaction happened on Apr 16 ’24, when Company’s Chief Financial Officer sold 25,000 for $7.67, making the entire transaction worth $191,658. This insider now owns 1,216,679 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Latest Financial update
In its latest quarterly report, released on 12/31/2023, the company reported earnings of -$0.42 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Here are Recursion Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 36.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.86 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) saw its 5-day average volume 3.64 million, a negative change from its year-to-date volume of 6.56 million. As of the previous 9 days, the stock’s Stochastic %D was 14.25%. Additionally, its Average True Range was 0.61.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 13.68%, which indicates a significant decrease from 20.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.89% in the past 14 days, which was lower than the 95.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.62, while its 200-day Moving Average is $9.35. Nevertheless, the first resistance level for the watch stands at $7.86 in the near term. At $8.12, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.44. If the price goes on to break the first support level at $7.27, it is likely to go to the next support level at $6.95. The third support level lies at $6.69 if the price breaches the second support level.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
With a market capitalization of 1.64 billion, the company has a total of 234,653K Shares Outstanding. Currently, annual sales are 44,580 K while annual income is -328,070 K. The company’s previous quarter sales were 10,890 K while its latest quarter income was -93,000 K.
